Hefei Enrui Pharmaceutical

Hefei Enrui Pharmaceutical is a clinical-stage biopharmaceutical company based in Hefei, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on oncology, cardiovascular diseases, and metabolic disorders, with a specialized expertise in multi-target kinase inhibitors. Its lead clinical candidate, Enruitinib (ER-001), is a potent multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR, currently undergoing Phase 2 clinical trials for various solid tumors including gastric and lung cancers. Enrui Pharmaceutical maintains integrated R&D and manufacturing capabilities, aiming to deliver high-quality and affordable therapeutic options to the global market.